{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:37:26Z","timestamp":1761871046351,"version":"build-2065373602"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.clml.2017.02.022","type":"journal-article","created":{"date-parts":[[2017,7,28]],"date-time":"2017-07-28T19:00:23Z","timestamp":1501268423000},"page":"S16-S25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"S","title":["Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune\u00a0Checkpoints"],"prefix":"10.1016","volume":"17","author":[{"given":"Juliana E.","family":"Hidalgo-L\u00f3pez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmi","family":"Kanagal-Shamanna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9s E.","family":"Quesada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beenu","family":"Thakral","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Mitsuhashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos E.","family":"Bueso-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.02.022_bib1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.022_bib2","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.clml.2016.08.005","article-title":"Changes in the updated 2016: WHO classification of the myelodysplastic syndromes and related myeloid neoplasms","volume":"16","author":"Bennett","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2017.02.022_bib3","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2016.66.9705","article-title":"Considering bone marrow blasts from nonerythroid cellularity improves the prognostic evaluation of myelodysplastic syndromes","volume":"34","author":"Arenillas","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.022_bib4","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/leu.2014.191","article-title":"Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes-proposal from the International\/European LeukemiaNet Working Group for Flow Cytometry in MDS","volume":"28","author":"Porwit","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.022_bib5","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.022_bib6","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.022_bib7","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.leu.2405070","article-title":"A\u00a0prognostic score for patients with lower risk myelodysplastic syndrome","volume":"22","author":"Garcia-Manero","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.022_bib8","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","author":"Prebet","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.022_bib9","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/cncr.29145","article-title":"Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium","volume":"121","author":"Jabbour","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.02.022_bib10","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.clml.2017.02.022_bib11","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.022_bib12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.clml.2017.02.022_bib13","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1002\/cncr.22570","article-title":"Myelodysplastic syndromes: incidence and survival in the United States","volume":"109","author":"Ma","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.02.022_bib14","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1182\/blood-2005-01-0040","article-title":"Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes","volume":"106","author":"Matsuda","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.022_bib15","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0165-4608(01)00392-2","article-title":"Chromosomal aberrations in Bloom syndrome patients with myeloid malignancies","volume":"128","author":"Poppe","year":"2001","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.clml.2017.02.022_bib16","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/blood.V93.2.459","article-title":"Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients","volume":"93","author":"Luna-Fineman","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.022_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/0145-2126(94)00141-V","article-title":"Occupational and environmental exposures and myelodysplasia: a case-control study","volume":"19","author":"West","year":"1995","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2017.02.022_bib18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1046\/j.1365-2141.1998.00963.x","article-title":"Exposure to myelotoxic agents and myelodysplasia: case-control study and correlation with clinicobiological findings","volume":"103","author":"Rigolin","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.02.022_bib19","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0145-2126(98)00135-0","article-title":"Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome","volume":"23","author":"Nagata","year":"1999","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2017.02.022_bib20","first-page":"939","article-title":"Occupational exposures and haematological malignancies: overview on human recent data","volume":"16","author":"Descatha","year":"2005","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.clml.2017.02.022_bib21","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1986.4.12.1748","article-title":"Therapy-related leukemia and myelodysplastic syndrome: clinical, cytogenetic, and prognostic features","volume":"4","author":"Kantarjian","year":"1986","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.022_bib22","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1182\/blood-2016-07-728766","article-title":"Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes","volume":"16","author":"Greenberg","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.022_bib23","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/leu.2014.161","article-title":"Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes","volume":"29","author":"Della Porta","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.022_bib24","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/modpathol.2013.187","article-title":"Bone marrow fibrosis in patients with primary myelodysplastic syndromes has prognostic value using current therapies and new risk stratification systems","volume":"27","author":"Fu","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clml.2017.02.022_bib25","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/bjh.13529","article-title":"TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis","volume":"171","author":"Loghavi","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.02.022_bib26","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.022_bib27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.022_bib28","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.022_bib29","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.022_bib30","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2013.52.3381","article-title":"Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation","volume":"32","author":"Bejar","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.022_bib31","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3324\/haematol.2013.098103","article-title":"p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q)","volume":"99","author":"Saft","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.02.022_bib32","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.022_bib33","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.022_bib34","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3389\/fonc.2016.00161","article-title":"Diagnostic utility of flow cytometry in myelodysplastic syndromes","volume":"6","author":"Aanei","year":"2016","journal-title":"Front Oncol"},{"key":"10.1016\/j.clml.2017.02.022_bib35","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1038\/leu.2012.30","article-title":"Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group","volume":"26","author":"Westers","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.022_bib36","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.hoc.2011.09.009","article-title":"Diagnosis of myelodysplastic syndromes in cytopenic patients","volume":"25","author":"Wang","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.clml.2017.02.022_bib37","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.leukres.2012.05.001","article-title":"Multi-color CD34(+) progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia","volume":"36","author":"Tang","year":"2012","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2017.02.022_bib38","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/cncr.23614","article-title":"Neutropenia in 6 ethnic groups from the Caribbean and the U.S","volume":"113","author":"Grann","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2017.02.022_bib39","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults\u00a0and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.022_bib40","doi-asserted-by":"crossref","first-page":"g5226","DOI":"10.1136\/bmj.g5226","article-title":"Vitamin B12 deficiency","volume":"349","author":"Hunt","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2017.02.022_bib41","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1182\/blood-2013-07-513242","article-title":"Neutropenia-associated ELANE mutations disrupting translation initiation produce novel neutrophil elastase isoforms","volume":"123","author":"Tidwell","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.022_bib42","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJMp0806821","article-title":"The many causes of severe congenital neutropenia","volume":"360","author":"Dale","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.022_bib43","doi-asserted-by":"crossref","first-page":"944","DOI":"10.3390\/ijms17060944","article-title":"Immune mechanisms in myelodysplastic syndrome","volume":"17","author":"Glenthoj","year":"2016","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clml.2017.02.022_bib44","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/asheducation-2015.1.299","article-title":"The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP)","volume":"2015","author":"Malcovati","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2017.02.022_bib45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrc3670","article-title":"Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy","volume":"14","author":"Coulie","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2017.02.022_bib46","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2017.02.022_bib47","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/leu.2015.69","article-title":"Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes","volume":"29","author":"Ganan-Gomez","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.022_bib48","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.022_bib49","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood.V96.12.3932","article-title":"The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS","volume":"96","author":"Parker","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.022_bib50","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1414799","article-title":"Somatic mutations and clonal hematopoiesis in aplastic anemia","volume":"373","author":"Yoshizato","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.022_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1440-1711.1999.00795.x","article-title":"The role of CTLA-4 in the regulation of T cell immune responses","volume":"77","author":"McCoy","year":"1999","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.clml.2017.02.022_bib52","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrc2051","article-title":"Immunostimulatory monoclonal antibodies for cancer therapy","volume":"7","author":"Melero","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2017.02.022_bib53","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1056\/NEJMra1514296","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.022_bib54","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.02.022_bib55","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N\u00a0Engl J Med"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016309119?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016309119?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:29:48Z","timestamp":1761870588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016309119"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":55,"alternative-id":["S2152265016309119"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.02.022","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune\u00a0Checkpoints","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}